AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18772180 — intervention group
Group type: COMPARATOR
Intervention: paclitaxel-eluting stent (PES)
Number of subjects: 79
Study 16465644 — intervention group
Group type: EXPERIMENTAL
Intervention: Methicillin-resistant Staphylococcus aureus (MRSA) colonization
Number of subjects: 22
Study 16465644 — intervention group
Group type: EXPERIMENTAL
Intervention: Methicillin-susceptible Staphylococcus aureus (MSSA) colonization
Number of subjects: 22
Study 16465644 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall colonization
Number of subjects: 22
Study 15248806 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive directional microphone setting
Number of subjects: 0
Study 15248806 — intervention group
Group type: COMPARATOR
Intervention: Fixed (cardioid) microphone setting
Number of subjects: 0
Study 12131639 — intervention group
Group type: EXPERIMENTAL
Intervention: Histoacryl Blue (HAB)
Number of subjects: 92
Study 12131639 — intervention group
Group type: COMPARATOR
Intervention: Suturing
Number of subjects: 92
Study 10454977 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban plus heparin and aspirin
Number of subjects: 100
Study 10454977 — intervention group
Group type: COMPARATOR
Intervention: Heparin and aspirin alone
Number of subjects: 100
Study 7531732 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (oral tablets) 10 mg twice daily
Number of subjects: 12
Study 7531732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2186802 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.75% irrigation
Number of subjects: 0
Study 2186802 — intervention group
Group type: COMPARATOR
Intervention: Control (no bupivacaine irrigation)
Number of subjects: 0
Study 399316 — intervention group
Group type: EXPERIMENTAL
Intervention: oestriol hemisuccinate (12 mg/day)
Number of subjects: 28
Study 399316 — intervention group
Group type: EXPERIMENTAL
Intervention: oestriol hemisuccinate (4-6 mg/day)
Number of subjects: 28
Study 399316 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 28
Study 31286829 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitch emphasis on the second word of the structure (modifier + N1 + N2)
Number of subjects: 0
Study 31286829 — intervention group
Group type: COMPARATOR
Intervention: No pitch emphasis on the second word of the structure (modifier + N1 + N2)
Number of subjects: 0
Study 31286829 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitch emphasis with visual context available
Number of subjects: 0
Study 31286829 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitch prominence interpreted as syntax-encoding
Number of subjects: 0
Study 29334176 — intervention group
Group type: EXPERIMENTAL
Intervention: LFCUD plus usual care (n = 33)
Number of subjects: 70
Study 29334176 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 37)
Number of subjects: 70
Study 27443664 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg pregabalin capsule (generic product)
Number of subjects: 0
Study 27443664 — intervention group
Group type: COMPARATOR
Intervention: 150 mg pregabalin capsule (reference brand Lyrica)
Number of subjects: 0
Study 25410607 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational workshop plus access to internet-based support resources
Number of subjects: 220
Study 25410607 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 220
Study 23217470 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional gas‐torch brazing (G-TB)
Number of subjects: 45
Study 23217470 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser welding (LW)
Number of subjects: 45
Study 23217470 — intervention group
Group type: EXPERIMENTAL
Intervention: Tungsten inert gas welding (TIG)
Number of subjects: 45
Study 20549166 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation applied to knee extensor muscles for 4 weeks (30-60 minutes, 5 days/week)
Number of subjects: 33
Study 20549166 — intervention group
Group type: COMPARATOR
Intervention: Sham-stimulation
Number of subjects: 33
Study 18722933 — intervention group
Group type: EXPERIMENTAL
Intervention: Colpopexy And Urinary Reduction Efforts (CARE) study
Number of subjects: 34
Study 18722933 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal Pelvic Symptoms and Patient Satisfaction After Colpocleisis cohort study
Number of subjects: 34
Study 18722933 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaires completed by 23 physician investigators and 11 nurses or coordinators
Number of subjects: 34
Study 18722933 — intervention group
Group type: EXPERIMENTAL
Intervention: Colpocleisis study
Number of subjects: 34
Study 18722933 — intervention group
Group type: COMPARATOR
Intervention: Older participants
Number of subjects: 34
Study 15950141 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation program over 1 year
Number of subjects: 86
Study 15950141 — intervention group
Group type: EXPERIMENTAL
Intervention: Body composition assessment using bioelectrical impedance (FFMI)
Number of subjects: 86
Study 11821829 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted distal gastrectomy (LADG)
Number of subjects: 28
Study 11821829 — intervention group
Group type: COMPARATOR
Intervention: Open distal gastrectomy (ODG)
Number of subjects: 28
Study 10212949 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) at 750 mg/day or 1.5 g/day
Number of subjects: 394
Study 10212949 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 394
Study 8702088 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir plus prednisone
Number of subjects: 208
Study 8702088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 1816110 — intervention group
Group type: EXPERIMENTAL
Intervention: Aciclovir (1,500 mg/m2/d)
Number of subjects: 43
Study 1816110 — intervention group
Group type: COMPARATOR
Intervention: Brivudin (15 mg/kg/d)
Number of subjects: 43
Study 6809442 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenon
Number of subjects: 0
Study 6809442 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine
Number of subjects: 0
Study 6809442 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocainide
Number of subjects: 0
Study 6809442 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide
Number of subjects: 0
Study 6809442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31982074 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (81 mg daily)
Number of subjects: 11976
Study 31982074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11976
Study 30168613 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylated DNA markers (MDMs) panel including HOXA1, EMX1, AK055957, ECE1, PFKP, CLEC11A normalized by B3GALT6 level
Number of subjects: 295
Study 30168613 — intervention group
Group type: COMPARATOR
Intervention: Alpha-fetoprotein (AFP)
Number of subjects: 295
Study 29849178 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (0.33 to 4.50 g EPA+DHA/day) for 14 days
Number of subjects: 303
Study 29849178 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed oil supplementation (5.90-6.60 g/d) for 14 days
Number of subjects: 303
Study 26227655 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants (n=266)
Number of subjects: 560
Study 26227655 — intervention group
Group type: COMPARATOR
Intervention: Non-participants (n=292)
Number of subjects: 560
Study 24594468 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial simulator training
Number of subjects: 27
Study 24594468 — intervention group
Group type: EXPERIMENTAL
Intervention: Live animal training
Number of subjects: 27
Study 24594468 — intervention group
Group type: EXPERIMENTAL
Intervention: Both training modalities
Number of subjects: 27
Study 22040016 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent‐Child Interaction Therapy Emotion Development (PCIT‐ED)
Number of subjects: 54
Study 22040016 — intervention group
Group type: COMPARATOR
Intervention: Psycho-education
Number of subjects: 54
Study 20582464 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline response (FEC and AC)
Number of subjects: 105
Study 20582464 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxane resistance (TET chemotherapy)
Number of subjects: 105
Study 20582464 — intervention group
Group type: EXPERIMENTAL
Intervention: AC responders (from FFPE samples)
Number of subjects: 105
Study 18048574 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (placebo, 5, or 10 mg) and Atorvastatin (placebo, 10, 20, 40, or 80 mg)
Number of subjects: 1660
Study 18048574 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment of atorvastatin and amlodipine
Number of subjects: 1660
Study 16221232 — intervention group
Group type: EXPERIMENTAL
Intervention: HB‐AS04 vaccine (Fendrix, GlaxoSmithKline Biologicals)
Number of subjects: 119
Study 16221232 — intervention group
Group type: COMPARATOR
Intervention: Standard vaccine (Engerix, GlaxoSmithKline Biologicals)
Number of subjects: 119
Study 16221232 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 119
Study 12361241 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH)
Number of subjects: 16
Study 12361241 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 16
Study 9987467 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based resistance exercise training
Number of subjects: 215
Study 9987467 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 215
Study 7757309 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg nimodipine t.i.d. for 7 days
Number of subjects: 12
Study 7757309 — intervention group
Group type: COMPARATOR
Intervention: nifedipine
Number of subjects: 12
Study 7757309 — intervention group
Group type: COMPARATOR
Intervention: nimodipine
Number of subjects: 12
Study 7757309 — intervention group
Group type: COMPARATOR
Intervention: nimodipine and nifedipine
Number of subjects: 12
Study 1554276 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 40
Study 1554276 — intervention group
Group type: COMPARATOR
Intervention: Packed red blood cells (PC)
Number of subjects: 40
Study 3998617 — intervention group
Group type: EXPERIMENTAL
Intervention: [1‐13C]stearic acid
Number of subjects: 6
Study 3998617 — intervention group
Group type: EXPERIMENTAL
Intervention: [1‐13C]oleic acid
Number of subjects: 6
Study 3998617 — intervention group
Group type: EXPERIMENTAL
Intervention: [1‐13C]linoleic acid
Number of subjects: 6
Study 31987248 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean red ginseng (KRG) 3 g for 6 weeks
Number of subjects: 50
Study 31987248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 29556335 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium diet (150 mmol sodium intake per day)
Number of subjects: 103
Study 29556335 — intervention group
Group type: COMPARATOR
Intervention: Low sodium diet (50 mmol sodium intake per day)
Number of subjects: 103
Study 29556335 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with β‐aminoisobutyric acid in Dahl salt-sensitive rats
Number of subjects: 103
Study 25731657 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbetocin (100 μg IM)
Number of subjects: 200
Study 25731657 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin (5 IU IM)
Number of subjects: 200
Study 25257612 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised progressive resistance training (PRT) for 24 weeks
Number of subjects: 0
Study 25257612 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-guided physical activity after 24 weeks of supervised PRT
Number of subjects: 0
Study 25257612 — intervention group
Group type: COMPARATOR
Intervention: Waitlist group undergoing supervised PRT after 24 weeks of habitual lifestyle
Number of subjects: 0
Study 23418994 — intervention group
Group type: EXPERIMENTAL
Intervention: TABADO program (community-based smoking cessation program) including general information session, small-group sessions, individual counselling, and nicotine therapy if needed.
Number of subjects: 1814
Study 23418994 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention, only usual educational services).
Number of subjects: 1814
Study 21219392 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser (ERL)
Number of subjects: 32
Study 21219392 — intervention group
Group type: COMPARATOR
Intervention: Plastic curets + cotton pellets + sterile saline (CPS)
Number of subjects: 32
Study 17634853 — intervention group
Group type: EXPERIMENTAL
Intervention: Monarc sling (n = 80)
Number of subjects: 187
Study 17634853 — intervention group
Group type: COMPARATOR
Intervention: TVT (n = 107)
Number of subjects: 187
Study 16476840 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa at a dose of 10,000 U thrice weekly s.c.
Number of subjects: 316
Study 16476840 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 316
Study 12924540 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 combined with HAART
Number of subjects: 70
Study 12924540 — intervention group
Group type: COMPARATOR
Intervention: HAART alone
Number of subjects: 70
Study 12924540 — intervention group
Group type: COMPARATOR
Intervention: IL-2 (after 6 months)
Number of subjects: 70
Study 10607690 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA) during induction and maintenance therapy
Number of subjects: 44
Study 10607690 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy without further ATRA
Number of subjects: 44
Study 10607690 — intervention group
Group type: EXPERIMENTAL
Intervention: No ATRA and no chemotherapy
Number of subjects: 44
Study 10607690 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy with ATRA
Number of subjects: 44
Study 9624473 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim (TMP) 10 mg/kg/day and Sulfamethoxazole (SMX) 50 mg/kg/day
Number of subjects: 77
Study 9624473 — intervention group
Group type: COMPARATOR
Intervention: Pyrimethamine (P) 50 mg/day and Sulfadiazine (S) 60 mg/kg/day
Number of subjects: 77
Study 8174727 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreserved oocytes
Number of subjects: 254
Study 8174727 — intervention group
Group type: COMPARATOR
Intervention: Control oocytes
Number of subjects: 254
Study 2966017 — intervention group
Group type: EXPERIMENTAL
Intervention: t‐PA 25 mg and UK 0.5 million U (group I)
Number of subjects: 146
Study 2966017 — intervention group
Group type: EXPERIMENTAL
Intervention: t‐PA 25 mg and UK 1.0 million U (group II)
Number of subjects: 146
Study 2966017 — intervention group
Group type: EXPERIMENTAL
Intervention: t‐PA 1.0 mg/kg and UK 0.5 million U (group III)
Number of subjects: 146
Study 2966017 — intervention group
Group type: EXPERIMENTAL
Intervention: t‐PA 1.0 mg/kg and UK 1.0 million U (group IV)
Number of subjects: 146
Study 2966017 — intervention group
Group type: EXPERIMENTAL
Intervention: t‐PA 1.0 mg/kg and UK 2.0 million U (group V)
Number of subjects: 146
Study 2966017 — intervention group
Group type: COMPARATOR
Intervention: t‐PA alone (previous study)
Number of subjects: 146
Study 29430801 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg combined with insulin
Number of subjects: 445
Study 29430801 — intervention group
Group type: COMPARATOR
Intervention: Insulin (glargine or lispro)
Number of subjects: 445
Study 27741182 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour interval administration of mifepristone and misoprostol
Number of subjects: 509
Study 27741182 — intervention group
Group type: COMPARATOR
Intervention: Simultaneous administration of mifepristone and misoprostol
Number of subjects: 509
Study 25133876 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (ICS) for 8 weeks
Number of subjects: 43
Study 25133876 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-25 measurements
Number of subjects: 43
Study 25133876 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma IL-25 levels
Number of subjects: 43
Study 22627969 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided foam sclerotherapy (UGFS)
Number of subjects: 430
Study 22627969 — intervention group
Group type: COMPARATOR
Intervention: Surgery (GSV stripping)
Number of subjects: 430
Study 20194129 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% of maximum effort for 2 seconds
Number of subjects: 9
Study 20194129 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% of maximum effort for 4 seconds
Number of subjects: 9
Study 20194129 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% of maximum effort for 2 seconds
Number of subjects: 9
Study 20194129 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% of maximum effort for 4 seconds
Number of subjects: 9
Study 20194129 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% of maximum effort for 1 second
Number of subjects: 9
Study 20194129 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% of maximum effort for 1 second
Number of subjects: 9
Study 20194129 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% of maximum effort for 5 seconds
Number of subjects: 9
Study 20194129 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% of maximum effort for 5 seconds
Number of subjects: 9
Study 18581184 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue (MB) dye
Number of subjects: 159
Study 18581184 — intervention group
Group type: COMPARATOR
Intervention: Lymphazurin blue (LB) dye
Number of subjects: 159
Study 16051646 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg sildenafil
Number of subjects: 28
Study 16051646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 11836010 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin (40 IU, intranasally)
Number of subjects: 0
Study 11836010 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 8573621 — intervention group
Group type: COMPARATOR
Intervention: AdCFTR (2 x 10^5 to 2 x 10^8.5 plaque forming units) administered to the nasal epithelium of one nostril
Number of subjects: 9
Study 8573621 — intervention group
Group type: COMPARATOR
Intervention: Control nostril (untreated)
Number of subjects: 9
Study 2596317 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide 20 mg/kg/day
Number of subjects: 20
Study 2596317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31504868 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing maintenance methadone dose by 30%
Number of subjects: 17
Study 31504868 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding oxycodone
Number of subjects: 17
Study 31504868 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding a single dose of gabapentin
Number of subjects: 17
Study 31504868 — intervention group
Group type: COMPARATOR
Intervention: Control condition (usual OAT dose)
Number of subjects: 17
Study 31389824 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial artery
Number of subjects: 0
Study 31389824 — intervention group
Group type: EXPERIMENTAL
Intervention: Right internal thoracic artery (RITA)
Number of subjects: 0
Study 31389824 — intervention group
Group type: COMPARATOR
Intervention: Bilateral internal thoracic artery (BITA)
Number of subjects: 0
Study 31389824 — intervention group
Group type: COMPARATOR
Intervention: Saphenous vein grafts (SVG)
Number of subjects: 0
Study 27849406 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedle fractional radiofrequency system (MFRS) - deep dermal layer
Number of subjects: 13
Study 27849406 — intervention group
Group type: COMPARATOR
Intervention: Microneedle fractional radiofrequency system (MFRS) - superficial dermal layer
Number of subjects: 13
Study 26086157 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrocolic gastroenteric reconstruction
Number of subjects: 73
Study 26086157 — intervention group
Group type: COMPARATOR
Intervention: Antecolic gastroenteric reconstruction
Number of subjects: 73
Study 26086157 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed gastric emptying (DGE)
Number of subjects: 73
Study 24803841 — intervention group
Group type: EXPERIMENTAL
Intervention: DDDR plus Atrial Preference Pacing (APP) algorithm (APP ON group)
Number of subjects: 60
Study 24803841 — intervention group
Group type: COMPARATOR
Intervention: Conventional dual-chamber pacing mode (DDDR group)
Number of subjects: 60
Study 21756523 — intervention group
Group type: EXPERIMENTAL
Intervention: IV methylprednisolone (MP) followed by oral MP (125 mg bolus, followed by 40 mg 6 hourly and then oral MP 0.6 mg/kg/day for 2 weeks)
Number of subjects: 97
Study 21756523 — intervention group
Group type: COMPARATOR
Intervention: IV hydrocortisone (HC) followed by oral prednisolone (200 mg 6 hourly until discharge, followed by prednisolone 0.75 mg/kg/day for 2 weeks)
Number of subjects: 97
Study 19888784 — intervention group
Group type: EXPERIMENTAL
Intervention: ALO-01 whole (60 mg capsules)
Number of subjects: 0
Study 19888784 — intervention group
Group type: EXPERIMENTAL
Intervention: ALO-01 crushed (60 mg capsules)
Number of subjects: 0
Study 19888784 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine sulfate solution (MSS) (120 mg)
Number of subjects: 0
Study 19888784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17222897 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-modal related probes
Number of subjects: 0
Study 17222897 — intervention group
Group type: COMPARATOR
Intervention: Speech-only related probes
Number of subjects: 0
Study 17222897 — intervention group
Group type: COMPARATOR
Intervention: Unrelated probes
Number of subjects: 0
Study 15495903 — intervention group
Group type: EXPERIMENTAL
Intervention: Syllables with only one cue to stress (spectral tilt)
Number of subjects: 2
Study 15495903 — intervention group
Group type: EXPERIMENTAL
Intervention: Syllables with multiple cues to stress
Number of subjects: 2
Study 15495903 — intervention group
Group type: COMPARATOR
Intervention: Syllables marked only by spectral tilt
Number of subjects: 2
Study 15495903 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress cues usage
Number of subjects: 2
Study 11485129 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy consultation
Number of subjects: 0
Study 11485129 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care (Control)
Number of subjects: 0
Study 9590315 — intervention group
Group type: EXPERIMENTAL
Intervention: TPN-glucose (75% glucose)
Number of subjects: 16
Study 9590315 — intervention group
Group type: COMPARATOR
Intervention: TPN-lipid (15% glucose)
Number of subjects: 16